RIF1 and neoplasm: All the mice that had been cured of RIF-1 EGFP tumours by BPD-PDT rejected the subsequent tumour rechallenge (0 out of eight grew tumours), while all of the surgically cured mice (five out of five), and all of the naïve mice that were challenged with RIF-1 EGFP cells grew tumours (five out of five).